Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.

"We are encouraged by the breadth of data from our Proteasome Inhibitor franchise being presented this year at ASH, which add to the clinical data of carfilzomib in combination with other therapies and provide further insight into the level of response for carfilzomib at a molecular level. Additionally, data to be presented on oprozomib offer clinical insights instrumental in driving forward our clinical development program for the compound," said Pablo Cagnoni, M.D., President of Onyx Pharmaceuticals, Inc.  "We remain committed to bringing innovative therapies to patients in need, and we look forward to playing a continued role in advancing the scientific understanding of hematologic malignancies."

Among the presentations are five abstracts from the Proteasome Research and Integrative Science for Multiple Myeloma – Novel Therapies Program (PRISM NTP), a global research collaboration between Onyx, investigators at myeloma centers of excellence and partner companies with novel therapies in development. "The PRISM program further demonstrates our commitment to innovation and advancing science," said Homa Yeganegi, Vice President of Scientific Affairs a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... , NEWTON, Mass., Aug. 6 ... Company will release second quarter 2009 financial results on Tuesday, ... , , Michael C. Ferrara, President and Chief ... Chief Accounting Officer, will host a conference call and live audio ...
... , , , ... SQNM ), today reported its financial results for the quarter ended June 30, ... Second Quarter Results , , Total ... million for the second quarter of 2008. The decrease from the comparable period ...
... ... Of Its New And Improved Website. The New Site Provides Users With A Comprehensive ... And Navigation. The Site Also Offers An Expanded Service Description For Each Of Its ... ...
Cached Biology Technology:Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 10One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2
(Date:4/17/2014)... Mo. April 17 In the most densely forested ... forests reflect two centuries of human needs, values and ... and clearing forests for agriculture and development, have set ... a U.S. Forest Service study reports. , The report ... conditions and management needs in the Northern United States ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... This news release is available in German . ... enable us to recognise objects; they also provide us with ... we run, turn around, fall or sit still in a ... characteristic motion trace on our retinas. Seemingly without effort, our ... can maintain a stable position and a steady gaze during ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... have been described as "molecular switches" and play a ... expression, and multiple other common cellular functions. ... illuminating cellular mechanisms related to cancer, which is fundamentally ... too rapidly, multiply and migrate into inappropriate places in ...
... Field, director of the Carnegie Institution,s Department of Global ... in the sciences, the humanities and the arts, business, ... elected to the new class of members of the ... of the world,s most prestigious honorary societies, cited Field ...
... Not all animals crave green spaces. Some thrive in ... will be addressed by Danielle Dagenais, a professor at the ... the Sommet sur la biodiversit et le verdissement de Montral ... interesting case studies is the Black Redstart. This small bird ...
Cached Biology News:Research pinpoints action of protein linked to key molecular switch 2Carnegie's Chris Field elected to American Academy of Arts & Sciences 2Urban wildlife: Some birds crave cement, not trees 2
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
Goat polyclonal to Lipocalin 2...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
... The INK4a-ARF locus encodes two unrelated ... suppression. p14^ARF^ arrests the cell cycle in ... and promotes the rapid degradation of mdm2 ... stabilization and accumulation. This interaction is ...
Biology Products: